ArticleAlzheimer's & dementia (New York, N. Y.)
Rationale and design of the ABOARD project (A Personalized Medicine Approach for Alzheimer's Disease).
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- A tool supporting person-centred communication among people with cognitive complaints, care partners, and clinicians: a feasibility study.PEC innovation · 2026Article
- Evaluation and lessons learned regarding Public Involvement: a panel advising on an Alzheimer's disease and related dementia cohort study.Research involvement and engagement · 2026Article
- Bridging research and practice for dementia care: strategies and challenges of public and private funders in the dissemination and implementation of dementia research.Health research policy and systems · 2026Article
- Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly.Alzheimer's research & therapy · 2025Article
- Digital Tools for People Without an Alzheimer Disease or Dementia Diagnosis: Scoping Review.Journal of medical Internet research · 2025Article
- Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Towards a national registry for Alzheimer's disease and related dementias: rationale, design, and initial observations of the ABOARD cohort.Alzheimer's research & therapy · 2025Article
- Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry).The journal of prevention of Alzheimer's disease · 2025Article
- Exploring interdisciplinary perspectives on the implementation ofJournal of Alzheimer's disease : JAD · 2025Article
- Examining resilience to Alzheimer's disease through the lens of monoaminergic neuromodulator systems.Trends in neurosciences · 2024Review
- Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic.Alzheimer's research & therapy · 2024Observational
- Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia.Neurology · 2024Article
- Cognitively healthy centenarians are genetically protected against Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Recognition of cognitive dysfunction in hospitalised older patients: a flash mob study.BMC geriatrics · 2024Observational
- Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.The journal of prevention of Alzheimer's disease · 2024Article
- Precision medicine in neurodegeneration: the IHI-PROMINENT project.Frontiers in neurology · 2023Article
- Rationale and design of the ABOARD project (A Personalized Medicine Approach for Alzheimer's Disease).Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key to stopping Alzheimer's disease (AD) lies in the pre-dementia stages, with the goal to stop AD before dementia has started. We present the rationale and design of the ABOARD (A Personalized Medicine Approach for Alzheimer's Disease) project, which aims to invest in personalized medicine for AD. ABOARD is a Dutch public-private partnership of 32 partners, connecting stakeholders from a scientific, clinical, and societal perspective. The 5-year project is structured into five work packages on (1) diagnosis, (2) prediction, (3) prevention, (4) patient-orchestrated care, and (5) communication and dissemination. ABOARD functions as a network organization in which professionals interact cross-sectorally. ABOARD has a strong junior training program "Juniors On Board." Project results are shared with society through multiple communication resources. By including relevant partners and involving citizens at risk, patients, and their care partners, ABOARD builds toward a future with personalized medicine for AD. Highlights: ABOARD (A Personalized Medicine Approach for Alzheimer's Disease) is a public-private research project executed by 32 partners that functions as a network organization.Together, the project partners build toward a future with personalized medicine for Alzheimer's disease.Although ABOARD is a Dutch consortium, it has international relevance.ABOARD improves diagnosis, prediction, prevention, and patient-orchestrated care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.